Size, Share & Industry Analysis, By Type (Technetium-99m (Tc-99m) Based Agents, Iodine-123 (I-123) Based Agents, Gallium-67 (Ga-67), Indium-111 (In-111) Based Agents, Thallium-201 (Tl-201)), By Application (Cardiac Imaging, Cancer Imaging, Brain Imaging, Thyroid Imaging, Infection and Inflammation Imaging), By End User (Hospitals, Diagnostic Imaging Centers, Academic & Research Institutions), By Isotope Supply Chain (Nuclear Reactor Produced, Cyclotron Produced, Generator Produced (Mo-99/Tc-99m)), and Global Forecast, 2026?2034
Explore the report section by section.
The global SPECT Radiopharmaceuticals Market generated USD 1.9 billion in 2025 and is estimated at USD 2.0 billion in 2026. Sales of single-photon imaging agents, related preparation kits and radioisotope generators are projected to reach USD 3.5 billion by 2034, a 7.2% CAGR during 2026–2034.
Single-photon emission computed tomography (SPECT) uses gamma-emitting tracers to assess myocardial perfusion, renal function, skeletal disease, infection and specific neurologic disorders. The commercial boundary covers radiopharmaceutical doses, sterile labelling kits, isotope generators and directly linked radiopharmacy preparation. It excludes PET agents such as fluorine-18, ultrasound contrast, scanners and therapeutic isotopes supplied for treatment rather than diagnosis.
Technetium-99m is the economic centre of this category because a single parent-isotope generator supplies many different approved imaging kits. The European Commission identifies Tc-99m as the workhorse of medical diagnostics; a North American hospital network orders time-sensitive, patient-specific doses through pharmacy distribution rather than storing radioactive inventory. That operating model favours suppliers with regional production, quality control and dependable scheduled transport.
Public financial reporting sets essential limits on the market boundary. Cardinal Health disclosed USD 1.578 billion for its 2025 Nuclear and Precision Health Solutions activities, but the division also covers PET and other services. Jubilant Pharmova separately reports radiopharmaceutical and radiopharmacy operations, again including activity outside single-photon tracers. Counting these whole divisions as SPECT would overstate the market, so revenue is assigned only to in-scope offerings.
Supply security and diagnostic appropriateness will influence growth more than premium pricing. The OECD Nuclear Energy Agency has documented reactor scheduling and isotope-chain vulnerabilities, while Curium received U.S. approval for a generic Tc-99m DTPA kit in April 2025. The subsequent transfer of Lantheus' SPECT products to SHINE in January 2026 demonstrates continued commercial investment in established tracers despite the rapid rise of PET-based oncology imaging.
Source: Cardinal Health FY2025; Jubilant Pharmova results; OECD isotope supply review; Curium FDA approval.
The market comprises gamma-emitting diagnostic radiopharmaceuticals and their generators, labelling kits and pharmacy-prepared doses used in SPECT and related gamma-camera imaging. Applications and supplier arrangements are assessed without counting scanner sales, PET tracers or therapeutic radionuclides.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD million/billion |
| By Type | Technetium-99m (Tc-99m) Based Agents; Iodine-123 (I-123) Based Agents; Gallium-67 (Ga-67); Indium-111 (In-111) Based Agents; Thallium-201 (Tl-201) |
| By Application | Cardiac Imaging; Cancer Imaging; Brain Imaging; Thyroid Imaging; Infection and Inflammation Imaging |
| By End User | Hospitals; Diagnostic Imaging Centers; Academic & Research Institutions |
| By Isotope Supply Chain | Nuclear Reactor Produced; Cyclotron Produced; Generator Produced (Mo-99/Tc-99m) |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Selected Countries | United States; Canada; United Kingdom; Belgium; Australia; India; Brazil; Mexico; South Africa; United Arab Emirates |
| Key Market Players | Cardinal Health; Curium Pharma; Jubilant Radiopharma; GE HealthCare; SHINE Technologies; Cyclopharm Limited; NTP Radioisotopes; IRE / IRE ELiT; BWXT Medical; Sun Radiopharma; ANSTO Nuclear Medicine |
Revenue counts the final sale of in-scope SPECT radiopharmaceuticals, labelled single-patient doses, essential nonradioactive kits and Mo-99/Tc-99m generators. Upstream isotope transactions embedded in downstream dose prices are not added again; distribution revenue is included only where it reflects the finished dose sold to a clinical customer. SPECT/CT service fees, camera hardware, PET and radioisotope cancer treatments are outside this category.
The publisher's four dimensions are preserved. Isotope Supply Chain identifies the principal last-mile route for the administered tracer: generator elution, direct reactor-derived supply or cyclotron-derived supply. It is not a tally of both initial Mo-99 irradiation and later Tc-99m generator elution. The reported "Cancer Imaging" application includes skeletal metastatic imaging and sentinel-node diagnostics; "Thyroid Imaging" refers to diagnostic use, not iodine-131 therapy.
Coronary artery assessment remains a repeatable source of SPECT use because perfusion tracers provide functional evidence alongside anatomical tests. GE HealthCare markets Myoview, a technetium-99m tetrofosmin kit for stress and resting myocardial imaging. The American Society of Nuclear Cardiology updated guidance for nuclear stress testing in 2026, sustaining standardized decision pathways. Hospital networks buy these agents as patient-specific prescriptions, creating recurring radiopharmacy throughput even where PET and CT have expanded. Growth therefore reflects more diagnostic episodes and efficient scheduling, not a uniform increase in tracer prices.
Most technetium-99m doses depend on a molybdenum-99 precursor from a limited network of research reactors and processing plants. The OECD Nuclear Energy Agency reviewed isotope-chain vulnerabilities in 2025, including reserve capacity and coordination across the production network. A reactor outage can disrupt daily appointments within days because decay prevents conventional stockpiling. Producers must invest in alternative routes, contingency sourcing and distributor agreements to defend existing volumes. Resilience spending supports stable service quality but can increase the delivered cost of individual doses.
Hybrid SPECT/CT supports anatomical localization and improves interpretation of single-photon signal. A 2025 Taiwanese cardiology consensus recommended careful Tc-99m pyrophosphate SPECT/CT interpretation for transthyretin cardiac amyloidosis to distinguish genuine myocardial uptake from blood-pool activity. Greater recognition of amyloid cardiomyopathy creates a specific testing indication beyond traditional coronary perfusion studies. However, growth depends on referral pathways and accurate reader training; false-positive imaging and incomplete evaluation for light-chain disease can erode clinician confidence and waste radiotracer capacity.
Proprietary PET oncology tracers increasingly compete with older gamma-camera examinations in prostate cancer and selected neurological settings. Lantheus sold its SPECT portfolio to SHINE in January 2026 while concentrating its retained activity on PET diagnostics and other imaging technologies. That transaction underscores a bifurcation between high-growth PET development and durable but price-sensitive SPECT demand. SPECT retains advantages where installed gamma cameras, lower-cost isotope kits and local radiopharmacy logistics allow broader access, particularly outside major academic centers.
Radioactive tracers require sterile preparation, release testing, trained pharmacists, radiation safeguards and reliable transport; clinical doses cannot be stored like ordinary medicines. Jubilant Radiopharmacies lists 42 U.S. SPECT pharmacies, demonstrating the logistical scale needed to serve a distributed hospital network. Small or rural facilities face the greatest friction because low-volume orders carry disproportionate delivery and compliance costs. Consolidated pharmacy routes and better generator availability can reduce cancellations, but no reimbursement policy eliminates the physical limits imposed by a six-hour technetium half-life.
Sources: GE HealthCare Myoview; American Society of Nuclear Cardiology; OECD Nuclear Energy Agency; Taiwan 2025 consensus; SHINE Technologies; Jubilant Radiopharmacies.
Curium announced U.S. FDA approval of a generic technetium-99m pentetate preparation kit on 2 April 2025. DTPA is used for lung ventilation imaging, with perfusion agents completing investigation of suspected pulmonary embolism. A second established supplier can reduce procurement vulnerability for nuclear-medicine departments that rely on combined ventilation/perfusion protocols. This commercial development is more likely to preserve dose availability and exert price pressure than to transform the overall size of diagnostic nuclear medicine. Demand still hinges on clinician selection between V/Q imaging and CT pulmonary angiography.
Lantheus completed the sale of TechneLite, Cardiolite, Neurolite and other legacy SPECT products to SHINE in January 2026. The transaction transferred manufacturing assets and Canadian operations along with familiar tracer brands. For customers, continuity of technical support and generator availability matters more than a change in corporate label. For suppliers, acquisition of mature product registrations can be a practical route to a nationwide prescription network without launching a new molecular entity. SHINE now competes through dedicated isotope and preparation capabilities rather than general diagnostic breadth.
On 10 September 2026, the European Commission adopted its Radioisotope Valley Initiative to improve regional isotope security and support investment. The framework addresses vulnerable upstream materials and ageing production infrastructure while maintaining clinical access to radioisotopes. Although therapeutic isotopes are a major element of the programme, diagnostic Mo-99 and Tc-99m pathways also benefit from more resilient processing and logistics. The practical opportunity for SPECT vendors is fewer missed examinations and more dependable contracts, not automatic reimbursement increases. Implementation will depend on reactor economics and national purchasing decisions.
Nuclear-cardiology societies continue to refine interpretation for myocardial perfusion and suspected amyloid disease. The 2025 peer-reviewed Tc-99m-PYP consensus emphasizes SPECT/CT localization and delayed-image acquisition to reduce blood-pool misinterpretation. Better protocols support clinicians considering a non-invasive test before advanced therapies, while keeping radiation exposure and ambiguous readings under review. The emerging revenue opportunity lies in higher-quality specialist referrals and associated repeatable dose orders. Clinical adoption will be limited where radiologists and cardiologists cannot align on image interpretation or patient selection.
Brazil's CNEN reported in April 2025 that generator and iodine production would be restored after a cyber incident at IPEN; India's BRIT lists several weekly Mo-99/Tc-99m generators and cold kits. These examples show that market access can depend on domestic radiochemical operations as much as demand for scanning. Regional suppliers investing in cyber resilience, scheduled maintenance and quality assurance can reduce exposure to international freight delays. Yet local generator output alone does not guarantee revenue growth without specialist staff, reliable cameras and a payer able to fund the examination.
SPECT imaging uses emitted gamma photons from administered radioisotopes, with radiopharmaceutical chemistry determining biological targeting and camera protocols determining image interpretation. Products differ materially in isotope half-life, clearance and clinical indication; modality-specific tracer supply remains distinct from PET and therapeutic radiopharmaceuticals.
| Agent or isotope | Primary clinical indication | Evidence or product status | Supply implication |
|---|---|---|---|
| Tc-99m tetrofosmin | Myocardial perfusion SPECT | GE HealthCare Myoview approved indication | Hospital or pharmacy-prepared short-lived doses |
| Tc-99m pentetate (DTPA) | V/Q imaging, renal imaging | Curium generic U.S. approval in April 2025 | Competing sterile kits and generators |
| I-123 FP-CIT | Selected tremor / parkinsonism differentiation | NICE recommends specialist use in selected cases | Cyclotron-origin radioiodine and specialist logistics |
| Tc-99m pyrophosphate | Transthyretin cardiac amyloidosis assessment | 2025 peer-reviewed consensus on SPECT interpretation | Reader training, appropriate patient referral |
| In-111 pentetreotide | Neuroendocrine imaging where available | Curium Octreoscan is an established product | Niche supply versus PET alternatives |
Technetium-99m can be complexed with different ligands for very different tests without changing the base radioisotope. Cardiac perfusion agents such as tetrofosmin and sestamibi are not clinically interchangeable with bone phosphonates or lung-perfusion macroaggregated albumin. Curium's marketed SPECT catalogue illustrates that the sector is a family of specialized registrations rather than a single isotope commodity. Because product authorization and kit availability vary by market, radiopharmacy portfolios are assembled locally around referral demand.
Iodine-123 FP-CIT provides an example of narrower specialty use. NICE recommends it only when a clinician cannot differentiate essential tremor from parkinsonism, and interpretation should remain with trained specialists. In the wider supply chain, IRE and NTP contribute isotope processing, while BRIT and ANSTO support generator-dependent access in Asia-Pacific. The European Medicines Agency's 2026 horizon scan identifies manufacturing quality and isotope security as cross-cutting requirements for radiopharmaceutical development.
Clinical differentiation will increasingly be about image confidence and total patient workflow. The 2025 Taiwan cardiac consensus stresses the value of delayed SPECT acquisition for myocardial amyloid evaluation, whereas Cyclopharm's Technegas deployment addresses lung ventilation imaging. Neither application should be presented as interchangeable with oncologic PET imaging. Commercially, tracer makers compete through documented indications, preparation reliability and local delivery rather than promising that every hybrid scanner creates an equivalent increase in drug revenue.
By Type, the SPECT Radiopharmaceuticals Market includes the publisher's five isotope classes. The Tc-99m class held an estimated ~78% of base-year sales, reflecting generator supply, cardiac kits and high-throughput routine diagnostics. The smaller classes are selected for distinct biological mechanisms, not as direct replacements for routine Tc-99m procedures.
Tc-99m preparation kits support myocardial perfusion, renal studies, lung perfusion and skeletal imaging. The six-hour physical half-life makes timely radiopharmacy delivery essential. Curium, Sun Radiopharma and GE HealthCare supply distinct FDA-labelled preparation kits, while isotope-generator capacity determines how many clinical doses can be dispensed locally.
I-123 products serve differentiated neurologic and endocrine imaging. NICE recommends FP-CIT SPECT in selected tremor cases when specialist examination cannot distinguish essential tremor from parkinsonism. The isotope has a different production and distribution pattern from Tc-99m, requiring reliable radioiodine suppliers and referral networks.
Gallium-67 remains available for certain infection, inflammation and oncologic assessments through nuclear pharmacies. Its longer biological pathway and imaging timetable make it less convenient than common Tc-99m agents for routine throughput. Clinical use continues where guideline-supported investigations or local resource constraints favour existing single-photon protocols.
Indium-111-labelled products include niche imaging of labelled white cells and selected somatostatin receptors. Curium markets Octreoscan as an established In-111 pentetreotide preparation kit. PET alternatives can displace some neuroendocrine indications, leaving infection investigations and specialty hospital contracts as more durable sources of demand.
Thallium-201 is a legacy cardiac tracer with limited contemporary procedural growth. It may remain in specialized myocardial protocols but faces competition from readily accessible Tc-99m sestamibi and tetrofosmin. Product availability, radiation-dose considerations and local scanner practices determine continuing orders rather than broad population screening.
The isotope category shares reflect finished-dose revenue, not equal numbers of patient examinations. Materials sold upstream for inclusion in downstream kits are counted only once.
The Application taxonomy distinguishes cardiac, oncologic, neurological, endocrine and infection-focused single-photon imaging demand. Cardiac Imaging led with an estimated ~39% of the base-year market, combining coronary perfusion and selected Tc-99m amyloid protocols. The clinical mix varies by reimbursement, access to PET and local specialty services.
Routine myocardial perfusion studies use established tracers such as GE HealthCare Myoview and generic Tc-99m sestamibi. The 2025 Taiwan consensus on pyrophosphate imaging describes a narrower referral group with suspected transthyretin cardiac amyloidosis. Recurring cardiology referrals sustain pharmacy contracts but require careful appropriateness assessments.
SPECT oncology volumes include bone-metastasis imaging, sentinel lymph-node mapping and selected receptor-specific scans. The importance of single-photon agents is indication-dependent: PET increasingly dominates some specialized cancer staging, while widely installed gamma cameras retain practical value for general oncology workups. Kit price and referral availability matter more than cancer prevalence alone.
I-123 ioflupane SPECT can help clinicians evaluate diagnostically uncertain tremor disorders; it is not a population-wide Parkinson screening method. Neurologic uptake requires trained interpreters and tightly timed appointments. Some Tc-99m brain perfusion and In-111 applications persist, but alternative molecular and structural imaging modalities moderate revenue expansion.
Diagnostic thyroid studies use iodine and technetium derivatives for selected functional assessments. These applications require differentiating tracer imaging from iodine-131 ablation therapy, which lies outside this market. Hospitals favour agents with well-established preparation practices and safety protocols, while clinical selection varies with thyroid laboratory results and ultrasound findings.
Radiolabelled white-cell imaging and gallium-based studies can evaluate difficult infection or inflammatory conditions when other techniques are inconclusive. Orders are episodic and concentrated in departments with expertise in tracer preparation and image interpretation. The commercial niche remains smaller than high-volume cardiac testing but can justify specialist supply relationships.
Clinical applications should not be treated as additive to the wider nuclear medicine and PET categories, which include different isotopes, equipment and therapeutic products.
By End User, the market serves Hospitals, Diagnostic Imaging Centers and Academic & Research Institutions. Hospital radiopharmacies and nuclear medicine departments remain the principal purchasers because they combine prescribing, radioactive-material permits and treatment decisions. Outpatient diagnostic centers account for a meaningful share of scheduled cardiac tests, while universities concentrate complex trials and rare tracer protocols.
Hospitals use SPECT agents across emergency assessment, inpatient cardiology, oncology and specialized nuclear medicine programs. Radiopharmaceutical deliveries are synchronized with scanner availability, pharmacists and patient preparation. Cleveland Clinic illustrates the breadth of molecular imaging departments, and hospital buyers often combine generator access with distributed pre-labelled doses for operational continuity.
Independent imaging centers can run predictable myocardial perfusion and bone-scan schedules with centralized dispensing. Their economics depend on patient referrals, payer contracts and the transport radius of a nearby nuclear pharmacy. Jubilant's SPECT distribution footprint illustrates why reliable routes can be as important to market share as isotope formulation.
Teaching hospitals and university research laboratories participate in tracer validation, specialized SPECT/CT protocols and isotope-supply research. Their commercial demand is modest relative to routine clinical sites, but they influence protocols and the uptake of advanced applications. Research materials intended only for laboratory use are not automatically counted as reimbursed diagnostic doses.
Purchaser categories are defined by the primary site administering the imaging product; suppliers serving both hospitals and independent clinics are assigned according to the actual purchasing organization.
By Isotope Supply Chain, the SPECT Radiopharmaceuticals Market uses the publisher's Nuclear Reactor Produced, Cyclotron Produced and Generator Produced (Mo-99/Tc-99m) categories. Generator Produced (Mo-99/Tc-99m) leads the final-dose route, with a reactor-manufactured parent isotope eluted at the clinical or pharmacy end of the chain. These classifications describe supply routes rather than counting the same material twice.
Direct reactor-derived tracers and upstream isotopes require irradiation scheduling, purification and cross-border shipping. IRE in Belgium and NTP in South Africa illustrate the importance of reliable reactor output and processing facilities. The category captures non-generator finished diagnostic pathways while avoiding double-counting reactor-produced Mo-99 later converted into a Tc-99m generator dose.
Cyclotron-based radionuclides include selected iodine products and specialised alternatives that do not use Mo-99 generators. Their commercial economics depend on target materials, accelerator uptime and accessible patient geography. They can provide supply diversification, although cyclotron-derived PET tracers are excluded from this SPECT-only market.
Mo-99/Tc-99m generators underpin high-volume nuclear cardiology and general imaging. ANSTO and India's BRIT describe regular generator distribution serving hospitals without on-site isotope production. This model creates predictable weekly replacement requirements but remains exposed to processing disruptions and time-critical freight across international borders.
The route classification assigns final radiopharmaceutical sales once, even though Mo-99 commonly begins in a reactor and is later eluted from a generator.
SPECT radiopharmaceutical demand depends on installed gamma-camera capacity, clinical pathways, insurance reimbursement and weekly isotope deliveries. Five regional revenue shares are distributed to sum to 100% for 2025. The country signals below concern documented local supply or clinical use; they do not imply invented country-level sales figures.
North America represented an estimated ~42% of 2025 revenue, with the United States carrying most commercial volume through distributed nuclear pharmacies, hospital service contracts and established reimbursed imaging. Cardiac SPECT remains an important routine service, although PET adoption is changing the diagnostic mix. The region has unusually strong public supplier disclosure: Cardinal Health reports Nuclear and Precision Health Solutions revenue, Lantheus historically sold Tc-99m products, and SHINE acquired those assets in 2026. These business totals cannot be treated as pure SPECT revenue because several also include PET or related services. Federal investment in domestic Mo-99 production may improve long-run reliability, while insurer policy and staffing remain barriers to smaller diagnostic sites. Canada shares the isotope-access problem without having the same domestic reactor-based Mo-99 production structure as in previous decades.
Cardinal Health disclosed USD 1.578 billion of fiscal-2025 Nuclear and Precision Health Solutions revenue, covering an assortment of radionuclide distribution and related services rather than SPECT alone. SHINE took over the TechneLite, Cardiolite and Neurolite franchises in January 2026, showing that established products retain value. Hospital demand depends on reimbursement, timely radiopharmacy deliveries and appropriate clinical referrals, while expanding PET oncology testing can change the modality mix.
Source: Cardinal Health 2025 Form 10-K.
Natural Resources Canada notes that its National Research Universal reactor stopped operations in 2018 and that the country consequently depends on foreign sources of Mo-99. The precursor is used to prepare Tc-99m for a large portion of diagnostic nuclear imaging. Canadian providers therefore need strong import logistics, isotope contingency planning and licensed nuclear medicine personnel to prevent cancelled tests. Domestic investment in other medical isotopes does not automatically restore historical Mo-99 availability.
Source: Natural Resources Canada.
Europe has extensive nuclear medicine infrastructure and an important upstream role in isotope irradiation, processing and generator distribution. The European Commission identifies more than 10 million radioisotope-based medical procedures annually and describes Europe as a major producer and exporter. Tc-99m is embedded in cardiology, oncology and selected neurological services, but individual countries make their own health-technology and procurement decisions. The September 2026 Radioisotope Valley Initiative prioritizes critical material access, production resilience and investment across the chain. Regional revenue growth should therefore follow continuity of reactor supply and standardized clinical demand rather than a universal premium-price expansion. UK recommendations for selective FP-CIT use and Belgian manufacturing capability illustrate why the provider and supplier sides must be considered separately in this region.
NICE recommends iodine-123 FP-CIT SPECT for patients with tremor when essential tremor cannot be distinguished clinically from parkinsonism, with specialist expertise required for interpretation. This defines a targeted neurological indication rather than an open-ended screening programme. Local radiopharmaceutical suppliers benefit when specialist services maintain predictable appointments and referral criteria. Continued use also depends on national nuclear-medicine workforce capacity and availability of imaging equipment in NHS facilities.
Source: NICE Parkinson guideline.
The Belgian Institute for Radioelements describes itself as a major molybdenum-99 producer serving technetium-99m generator manufacturers. Its business combines demanding reactor scheduling, radiochemical processing and international distribution rather than simply selling a finished diagnostic injection. This position gives Belgium strategic importance for many hospitals outside its borders. Commercial growth remains tied to maintaining isotope availability, quality systems and competitive supply contracts under evolving European production-security policy.
Source: IRE production profile.
Asia-Pacific includes mature nuclear medicine systems and lower-income markets with different access constraints. Australia uses a domestic isotope supply chain for Tc-99m generator shipments, while India operates public-sector generator and cold-kit production. Regional opportunities emerge where hospitals add licensed nuclear-medicine capacity and where specialized cardiology tests become more accessible. However, the economics vary widely: a hospital can own a SPECT/CT camera yet remain unable to run consistent lists if radioactive precursors arrive late. A 2025 cardiac-amyloidosis consensus published by clinicians in Taiwan illustrates how regional medical societies may improve image quality for focused indications. Competitive advantage is more closely associated with reliable supply, training and referral networks than with assuming every medical imaging upgrade increases radiopharmaceutical revenue.
ANSTO states that its Mo-99 facility supports an estimated 550,000 Australian patients each year and distributes technetium generators to hundreds of Australian and New Zealand hospitals and diagnostic services. That domestic production base reduces dependence on a single import corridor but does not remove decay-related delivery pressures. Reliable generator and cold-kit logistics help clinical providers offer bone, renal and cardiac studies beyond the largest metropolitan centres.
Source: ANSTO Mo-99 facility FAQ.
The Board of Radiation and Isotope Technology publishes several regular Mo-99/Tc-99m generator systems and a broad set of technetium cold kits. Its supply programme supports hospitals that cannot manufacture radioisotopes locally. The breadth of generators is commercially relevant because dose preparation, shelf life and local transport determine how many studies can proceed. Domestic output can expand practical availability, but reimbursement, camera maintenance and trained nuclear-medicine professionals still constrain patient access.
Source: BRIT SPECT product catalogue.
Latin America has clinical demand for nuclear cardiology, metastatic bone imaging and selected endocrine tests, but radiopharmaceutical availability differs by city and payer. National isotope institutions play a larger role in supply continuity than headline scanner-installation figures would suggest. Brazil faced a documented 2025 interruption in nuclear medicine production following a cybersecurity incident, underscoring operational rather than epidemiological limits on growth. Mexico maintains public technical expertise in technetium-99m and indigenous radiopharmaceutical development. Imported kits, licensing procedures and domestic isotope production all influence final delivered-dose cost. Because public reports generally describe capacity and interruptions rather than audited SPECT-drug sales, country market sizes are not inferred from demographics. The gradual commercialization path depends on stable radiochemistry facilities, regional transport and public-hospital access.
Brazil's National Nuclear Energy Commission reported that a March 2025 cyber incident disrupted IPEN operations, with testing intended to restore technetium generator and iodine production in April. That disruption illustrates how digital infrastructure failures can delay clinically indicated nuclear medicine examinations even when scanners and patients are available. Supply resilience, regulatory release testing and alternate procurement are therefore commercial priorities for Brazilian hospitals and isotope distributors.
Source: CNEN operational update.
Mexico's national nuclear research institute describes technetium-99m as a widely used isotope for gamma imaging and SPECT, including myocardial and skeletal studies. It explains the Mo-99 decay route and short Tc-99m half-life, which make diagnostic appointments dependent on synchronized supply. Local radiopharmaceutical research and education can strengthen clinical access, while uptake remains sensitive to institutional funding and delivery coverage beyond major urban medical centres.
Source: Mexico ININ clinical explanation.
Middle East and Africa combines major upstream isotope capacity with comparatively uneven downstream clinical access. South Africa hosts the SAFARI-1 reactor and NTP radiochemical processing, which supply an international Mo-99 customer base. That industrial role does not mean nuclear medicine examination rates are uniformly high across the continent; hospitals also need gamma cameras, radiopharmacists and reliable referral pathways. Selected Gulf health systems operate modern SPECT departments, creating opportunities for specialized diagnostic tracers and trained staff. Outside those facilities, transport restrictions and procurement budgets can limit throughput. The region's strategic position reflects manufacturing exports and locally concentrated hospital demand rather than a single national reimbursement model. Collaboration in training, quality assurance and isotope delivery would allow more consistent participation through the forecast period.
NTP Radioisotopes describes SAFARI-1-based production and purification of Mo-99 used in technetium generators, with batches coordinated around radioactive decay. The business serves international diagnostic users and provides South Africa with a rare upstream position in the global isotope chain. Local hospitals still need nuclear medicine infrastructure and purchasing resources to convert isotope supply into patient examinations. Production reliability is particularly important because backup shipments have a narrow viable window.
Source: NTP Mo-99 process.
Cleveland Clinic Abu Dhabi lists SPECT alongside PET in a multidisciplinary nuclear medicine service covering cardiac, skeletal, endocrine and cancer-related clinical indications. That represents a high-capability specialist provider model rather than proof of broad population access across the Gulf. Commercial demand for diagnostic agents depends on clinician referral patterns, appropriate use, local licensing and the ability to obtain scheduled doses at the hospital. Other regional systems may have very different resource constraints.
Source: Cleveland Clinic Abu Dhabi.
Patient access to SPECT diagnostics depends on authorization of the radiopharmaceutical, appropriate procedure reimbursement, specialist staffing and a reliable supply of short-lived radionuclides. A marketed isotope kit may still be unavailable to a particular hospital when dispensing capacity or local contracts are inadequate.
| Market / policy | Documented evidence | Barrier | Revenue implication |
|---|---|---|---|
| United States | Curium generic Tc-99m DTPA cleared in April 2025 | Payer coding and radioactive dose logistics | More sourcing choices for V/Q and renal scanning |
| U.S. isotope security | DOE outlined domestic Mo-99 financial support in 2025 | Imported precursor exposure and new plant capital | Possible supply stabilization, not new clinical indications |
| United Kingdom | NICE recommends I-123 FP-CIT only for selected tremor cases | Specialist referral and interpretation | Niche diagnostic demand with defined eligibility |
| European Union | European Radioisotope Valley Initiative adopted September 2026 | Ageing reactors and precursor dependence | Investment in long-run product availability |
| Australia | ANSTO Mo-99 generator shipments to clinical facilities | Distribution schedules across long distances | Supports routine patient access and continuity |
| Brazil | IPEN production disruption and recovery during 2025 | Cyber resilience and quality-release operations | Delayed examinations when supply chain fails |
Routine diagnostic agents are reimbursed very differently from branded PET tracers or therapeutic radionuclide medicines. In many facilities the hospital receives a packaged or separately coded payment for imaging and associated supplies, while a commercial nuclear pharmacy sells a prepared dose under a purchase agreement. The accepted price must cover radioactive decay losses, release testing, shielding and specialized delivery. GE HealthCare's Myoview clinical labelling shows why payment also relates to a specific appropriate indication rather than the presence of a gamma camera alone.
Access varies strongly by clinical use. NICE confines iodine-123 FP-CIT to specialist uncertainty around parkinsonism, whereas routinely ordered myocardial perfusion agents operate under separate cardiac workup protocols. The 2025 cardiac amyloid consensus likewise emphasizes correct patient selection and image interpretation; expanding use without those safeguards could increase equivocal studies instead of improving diagnostic confidence. Providers may favour reliable, lower-priced generic formulations provided they can maintain quality and avoid interruptions.
Finally, transport and parent-isotope availability create constraints no ordinary pharmaceutical price concession can solve. The OECD and Euratom agencies document dependency on limited Mo-99 reactor infrastructure. The European Commission's 2026 supply initiative and SHINE's U.S. expansion address the durability of that system. Hospitals can mitigate near-term cancellations through backup contracts and pharmacy coordination, but they cannot store Tc-99m for many weeks in anticipation of shortages.
Source: Curium FDA announcement; NICE specialist guidance; European Radioisotope Valley Initiative.
Product approvals, clinical guidelines and isotope manufacturing programmes provide different signals. Only the first changes an agent's approved use; professional consensus affects appropriate interpretation, while capacity projects improve the probability of receiving an eligible tracer on time.
| Date | Verified event | Regulatory or clinical status | SPECT relevance |
|---|---|---|---|
| October 2023 | FDA authorizes Technegas in the U.S. | Ventilation imaging product approval | New supply option in lung studies |
| January 2025 | Taiwan issues PYP SPECT/CT consensus | Peer-reviewed diagnostic practice | Supports carefully selected amyloid referrals |
| April 2025 | Curium generic Tc-99m DTPA kit authorized | U.S. FDA marketing approval | Second supplier for selected imaging services |
| April 2025 | Brazil IPEN works to restore radiopharmaceutical production | CNEN public operational statement | Domestic dose continuity remains vulnerable |
| January 2026 | SHINE closes Lantheus SPECT purchase | Completed commercial asset transfer | Control of historic Tc-99m brands changes |
| September 2026 | European Commission adopts ERVI | Regional isotope security strategy | Targets upstream capacity and strategic dependence |
Curium's April 2025 approval is for a generic DTPA kit used after Tc-99m labelling; it must not be described as approval of a new scanner or a new clinical indication for all single-photon tracers. Existing market authorizations specify indications, preparation conditions and safety information by product. The EMA review issued during 2026 highlights manufacturing-good-practice requirements for radiopharmaceuticals and continued vulnerability along the precursor supply chain.
Cyclopharm's Technegas authorization illustrates that modality innovation can also emerge from inhaled diagnostic particles in pulmonary medicine. Its United States deployment continued during 2025 and 2026, while its company reporting describes broader trials as development rather than guaranteed commercial approval. Cardiac amyloidosis consensus guidance creates a separate opportunity for Tc-99m pyrophosphate but cannot establish new reimbursed indications without clinician and payer acceptance.
Supply infrastructure is an additional regulatory and commercial dimension. Europe has prioritized radioisotope security, and the OECD tracks reactor outages and reserves; these policies are not equivalent to drug-approval announcements. Country-specific release tests, sterile compounding safeguards, radiological transport licensing and quality controls determine whether a product is fit to administer. Timely investment in those systems can support more reliable clinical access even when unit-dose prices remain under pressure.
Competition follows several different business models: specialist isotope producers, finished-kit manufacturers, generator suppliers and patient-dose radiopharmacies. Public disclosures are often grouped with PET or therapeutic services, so reported division revenue should not be interpreted as a SPECT-only ranking. The ownership transfer of familiar products to SHINE in 2026 highlights consolidation without a change in the basic clinical use of those products.
The company reported USD 1.578 billion for its broader Nuclear and Precision Health Solutions business in FY2025. Its scale supports dose logistics, but included activities extend beyond SPECT products.
The marketed U.S. catalogue includes Tc-99m sestamibi, DTPA, PYP, MAA, HDP and multiple specialty agents, with a 2025 generic DTPA approval widening customer supply options.
SHINE acquired TechneLite, Cardiolite, Neurolite and SPECT manufacturing operations from Lantheus at the start of 2026, positioning it in generator and branded-kit supply.
The company reports both radiopharmaceutical manufacture and radiopharmacy distribution, including 42 U.S. SPECT pharmacies, and serves clinical users through delivered preparations.
Myoview is an approved technetium tetrofosmin preparation for stress and rest myocardial perfusion assessment; GE participates through labelled tracer products in addition to imaging equipment.
Upstream suppliers add another layer of resilience. Belgium's IRE and South Africa's NTP provide Mo-99 processing capability; ANSTO distributes generators in Australia, and BWXT Medical describes an isotope portfolio and generator programme. Cyclopharm commercializes Technegas for ventilation imaging, while Sun Radiopharma manufactures several common SPECT kits. Their participation is verified by product or facility documentation rather than by assuming all medical-imaging companies sell radioactive diagnostics.
Successful commercial execution therefore requires breadth and discipline. Reliable payment cycles and isotope handling licences further influence which suppliers can serve rural customers efficiently. A pharmacy network can win hospital contracts through reliable unit-dose delivery, whereas a developer of a differentiated tracer needs clinical validation, approval and training to stimulate referrals. The sector remains vulnerable to reactor outages, product discontinuations and differences in national reimbursement. Buyers should separate finished-product sellers from businesses that supply only equipment or upstream precursors when assessing market concentration.
September 2026: The European Commission introduced the European Radioisotope Valley Initiative to reinforce medical isotope production, address strategic dependencies and support secure radionuclide supply. Its framework covers the upstream systems behind routine Tc-99m imaging as well as other medical isotopes. For SPECT providers, the effect should be measured through supply reliability and investment rather than assuming all measures immediately generate additional examinations. Source
January 2026: SHINE completed its acquisition of Lantheus' SPECT portfolio, including TechneLite generators, Cardiolite cardiac kits, Neurolite brain-imaging agents and related manufacturing. The transferred operations give SHINE established diagnostic product registrations and a customer base. The transaction changes commercial stewardship, while the clinical indications and need for controlled isotope deliveries remain substantially the same. Source
September 2025: The OECD Nuclear Energy Agency published an updated review of radioisotope supply and utilization challenges, detailing reactor scheduling, production resilience and infrastructure concerns. Because Mo-99 decays before it reaches nuclear pharmacies and hospitals, contingency capacity is central to maintaining examinations. That report supports investment in supply reliability, not an assumption of a guaranteed double-digit expansion in finished SPECT drug revenue. Source
April 2025: Curium received FDA clearance for its generic Tc-99m pentetate (DTPA) preparation kit. The formulation is used in ventilation imaging, renal assessment and selected other approved settings. Adding an established supplier to the U.S. market helps nuclear medicine providers manage procurement and may preserve clinical activity during a competitor outage, although it also creates competitive pricing pressure. Source
April 2025: Brazil's National Nuclear Energy Commission outlined work to restart radioisotope production following a cyber incident affecting IPEN in March. Restoring generator production required technical checks and controlled operational recovery. The event exposed a non-clinical vulnerability in patient access to nuclear medicine, illustrating why cyber resilience belongs in manufacturing continuity plans alongside reactor maintenance and radiochemical quality assurance. Source
January 2025: A peer-reviewed Taiwanese consensus updated the interpretation of technetium-99m pyrophosphate scintigraphy in suspected transthyretin cardiac amyloidosis. It emphasized SPECT/CT localization and attention to delayed imaging to reduce incorrect identification of residual blood-pool activity. Such clinical standardization can improve confidence in carefully selected cardiac referrals without automatically expanding licensed use or payer coverage. Source
Global sales of SPECT imaging agents begin at USD 2.0 billion for 2026 and are projected at USD 3.5 billion by 2034, a 7.2% compound annual increase. Volume growth reflects routine clinical demand, better access to generators and some new specialist applications, while price pressure and the migration of selected examinations to PET temper market value.
| Forecast driver | 2026 market position | Potential effect by 2034 |
|---|---|---|
| Cardiac diagnostics | Myoview, sestamibi and PYP protocols established | Gradual procedure growth where referral pathways expand |
| Generic isotope kits | Curium and other manufacturers compete in Tc-99m kits | More supply choices with limited price inflation |
| Isotope resilience | International Mo-99 chain with outage risk | Fewer cancelled studies after capacity investment |
| SPECT versus PET | Mature nuclear cardiology; PET rising in selected areas | Substitution offsets some tracer volume growth |
| Emerging-market access | Variable radiopharmacy delivery and scan capacity | Adoption improves with trained personnel and stable routes |
The early forecast period begins from an installed imaging base rather than a speculative one-product launch. Hospitals are expected to continue buying technetium agents for myocardial perfusion, skeletal imaging, renal procedures and pulmonary examinations. Curium's generic DTPA entry is a practical example of how alternate manufacturers can improve supply continuity. More competition may reduce revenue per prepared dose, so expansion in clinical examinations should not be mistaken for equivalent percentage growth in sales value.
Mid-decade performance will be tied to Mo-99 supply stability. A geographically diverse set of reactor and processing facilities reduces exposure to single-site problems, yet radioactive decay makes freight and generator scheduling permanent operating risks. European policy launched in 2026 and U.S. investment in domestic isotope supply could strengthen reliability if capacity projects reach sustainable operation. The commercial benefit lies in delivering booked tests on time and supporting regional nuclear pharmacy contracts, rather than relying on a sudden increase in the radioactive content price.
New clinical uses provide a selective upside. Cardiac amyloidosis imaging requires coordinated cardiology referrals and expertise in differentiating genuine myocardial uptake from blood pool. NICE's specialist recommendation for iodine-123 FP-CIT shows that some differentiated tracers can sustain valuable use while remaining far smaller than routine cardiovascular tests. Oncology-related SPECT, especially bone and node imaging, continues alongside PET rather than replacing the newer modality across every disease pathway.
North America should continue to contribute the largest share of revenue, while Europe remains important as both consumer and isotope supplier. Asia-Pacific can improve access through domestic generators and nuclear medicine training, with Latin America and parts of Africa constrained by infrastructure and procurement risks. The expected difference between volume and value growth is material: more diagnostic scans may coincide with greater generic use, lower net dose prices and a shift of premium oncology diagnostics into PET. Consequently, the forecast does not assume sales growth at the publisher's historical stated pace.
Coverage includes finished SPECT diagnostic radioisotope agents and associated dose-preparation supply, with an explicit boundary against adjacent PET, therapeutic radionuclide and medical equipment markets.
The SPECT Radiopharmaceuticals Market is estimated at **USD 1.9 billion in 2025** for gamma-emitting diagnostic agents, preparation kits and related finished doses. This revenue boundary excludes PET tracers, therapeutic radionuclides and imaging equipment. Commercial issuer accounts help test the estimate, but no single public filing isolates every supplier's global SPECT activity.
The projected compound annual growth rate is **7.2% for 2026–2034**, based on a USD 2.0 billion starting estimate and a USD 3.5 billion terminal forecast. Greater diagnostic access, routine cardiac imaging and isotope-supply investment support growth, while generic competition and PET substitution constrain net sales expansion.
Several SPECT products are approved for defined clinical uses, including technetium-99m tetrofosmin for myocardial perfusion and specific Tc-99m pentetate, sestamibi and pyrophosphate preparations. Curium received a U.S. generic DTPA-kit approval in April 2025. Clinicians must follow each product's particular preparation directions and indications; approval of one kit does not authorize all imaging purposes.
Neither SPECT nor PET is universally better for every cancer indication. PET often provides greater sensitivity for selected molecular targets, while SPECT and planar gamma imaging remain useful for skeletal metastases, sentinel nodes and other established procedures. Choice depends on the disease question, tracer availability, test accuracy, radiation exposure and local clinical guidelines.
North America leads the market, accounting for an estimated **~42% of 2025 revenue**. Extensive nuclear-pharmacy delivery services, longstanding myocardial perfusion protocols and reimbursement infrastructure support routine diagnostic use. European isotope production and developing Asia-Pacific clinical access also matter, but their supplier revenues should not be converted into country revenue estimates without audited evidence.
Medicare may cover medically necessary SPECT examinations and associated approved diagnostic radiopharmaceuticals under the applicable service, coding and site-of-care rules. Coverage is indication-specific rather than automatic for every tracer or screening request. Patients and providers should check the relevant Medicare administrative contractor and current outpatient payment policies before assuming a particular examination will be reimbursed.
Yes, generic technetium-99m imaging kits are available for certain approved uses. In April 2025, Curium announced FDA approval for its generic DTPA kit, providing an additional supplier for selected lung and renal procedures. Brand substitution still depends on matching regulatory indications, compatible preparation protocols and reliable local supply.
Key manufacturers and suppliers include Curium, Cardinal Health, Jubilant Radiopharma, GE HealthCare and SHINE Technologies. SHINE acquired established SPECT brands from Lantheus in January 2026; upstream isotope participants include IRE and NTP. Public segment reporting usually combines SPECT with PET or other nuclear services, preventing a defensible global vendor-share league table.
Mo-99 supply interruptions, rapid radioactive decay, specialized sterile preparation and dependence on licensed hospital personnel are major challenges. Suppliers also face alternative PET imaging tests and constrained payer budgets. The OECD reviewed isotope-chain vulnerabilities in 2025, while Brazil's IPEN disruption showed that even cybersecurity problems can interfere with the availability of clinically ordered tracers.
Common applications include coronary perfusion assessment, bone metastasis imaging, selected renal and thyroid studies and lung ventilation/perfusion evaluation. Iodine-123 FP-CIT can assist with certain diagnostically unclear tremor disorders, while Tc-99m pyrophosphate is used in carefully selected cardiac amyloidosis workups. The appropriate product depends on the clinical question and specialist judgement.
Technetium-99m is expected to remain the principal SPECT isotope because generators and diverse approved kits support many established clinical workflows. Its large installed base does not guarantee rapid price increases: recurring isotope supply costs, generic formulations and PET substitution influence market value. Capacity investment may improve reliability and procedure access over the forecast period.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.